Special Groups in Clinical Investigations: Incapacitated Subjects, Minors, Pregnant and Breastfeeding Women, Emergency Situations and Compensation for Damage (Tıbbi Cihaz Yönetmeliği Articles 64-69)

SUMMARY
The special group provisions for clinical investigations are in Articles 64 to 68 of the Tıbbi Cihaz Yönetmeliği (Medical Device Regulation): incapacitated subjects, minors, pregnant or breastfeeding women, groups for which additional measures may be taken, and emergency situations. For incapacitated subjects, minors and pregnant or breastfeeding women, all the conditions listed are required in addition to the conditions in the fourth paragraph of Article 62.
In this post we give these Articles, and Article 69, which regulates the compensation system for damage to subjects, as verbatim quotations from the text of the Regulation. Medex does not conduct clinical investigations; the subject is a transfer of the provisions of the Regulation.
For the ÜTS registration of your devices: Medical Device ÜTS Registration Consultancy
Contents
1. Common Framework: Article 62(4)
Clinical investigation is defined in Article 3; the fourth paragraph of Article 62 lists the conditions for conducting it and ties the special groups to Articles 64 to 68:
“(4) A clinical investigation as referred to in the first paragraph may be conducted only where all of the following conditions are met:”
“(ç) appropriate protection of vulnerable populations and subjects in accordance with Articles 64 to 68.”
“(e) the subject or, where the subject is not able to give informed consent, his or her legally designated representative has given informed consent in accordance with Article 63.”
For the application for investigational devices and clinical investigations, see our post on clinical investigation and investigational devices.
2. Clinical Investigations on Incapacitated Subjects: Article 64
“(1) In the case of incapacitated subjects who have not given, or have not refused to give, informed consent before the onset of their incapacity, a clinical investigation may be conducted only where, in addition to the conditions in the fourth paragraph of Article 62, all of the following conditions are met:”
“(a) the informed consent of their legally designated representative has been obtained;”
“(b) the incapacitated subjects have received the information referred to in the second paragraph of Article 63 in a way that is adequate in view of their capacity to understand it;”
“(c) the explicit wish of an incapacitated subject who is capable of forming an opinion and assessing the information referred to in the second paragraph of Article 63 to refuse participation in, or to withdraw from, the clinical investigation at any time, is respected by the investigator;”
“(ç) no incentives or financial inducements are given to the subjects or their legally designated representatives, except for compensation for expenses and loss of earnings directly related to the participation in the clinical investigation;”
“(d) the clinical investigation is essential with respect to incapacitated subjects and data of comparable validity cannot be obtained in clinical investigations on persons able to give informed consent or by other research methods;”
“(e) the clinical investigation relates directly to a medical condition from which the subject suffers;”
“(f) there are scientific grounds to expect that participation in the clinical investigation will produce a direct benefit to the incapacitated subject outweighing the risks and burdens involved.”
“(2) The subject shall as far as possible take part in the informed consent procedure.”
3. Clinical Investigations on Minors: Article 65
“(1) A clinical investigation on minors may be conducted only where, in addition to the conditions in the fourth paragraph of Article 62, all of the following conditions are met:”
“(a) the informed consent of their legally designated representative has been obtained;”
“(b) the minors have received the information referred to in the second paragraph of Article 63 in a way adapted to their age and mental maturity and from investigators or members of the investigating team who are trained or experienced in working with children;”
“(c) the explicit wish of a minor who is capable of forming an opinion and assessing the information referred to in the second paragraph of Article 63 to refuse participation in, or to withdraw from, the clinical investigation at any time, is respected by the investigator;”
“(ç) no incentives or financial inducements are given to the subjects or their legally designated representatives, except for compensation for expenses and loss of earnings directly related to the participation in the clinical investigation;”
“(d) the clinical investigation is intended to investigate treatments for a medical condition that occurs only in minors, or the clinical investigation on minors is essential to validate data obtained in clinical investigations on persons able to give informed consent or obtained by other research methods;”
“(e) the clinical investigation relates directly to a medical condition from which the minor concerned suffers, or is of such a nature that it can only be carried out on minors;”
“(f) there are scientific grounds to expect that participation in the clinical investigation will produce a direct benefit to the minor outweighing the risks and burdens involved.”
“(g) the minor takes part in the informed consent procedure in a way adapted to his or her age and mental maturity;”
“(ğ) if during a clinical investigation the minor reaches the age of legal capacity to give informed consent as defined in the relevant legislation, his or her explicit informed consent is obtained before that subject can continue to participate in the clinical investigation.”
The seventh paragraph of Article 63 preserves the legislation on the separate assent of the minor:
“(7) This Regulation shall not affect the relevant legislation requiring that, in addition to the informed consent given by the legally designated representative, a minor who is capable of forming an opinion and assessing the information given to him or her also gives his or her assent in order to participate in a clinical investigation.”
4. Clinical Investigations on Pregnant or Breastfeeding Women: Article 66
“(1) A clinical investigation on pregnant or breastfeeding women may be conducted only where, in addition to the conditions in the fourth paragraph of Article 62, all of the following conditions are met:”
“(a) the clinical investigation has the potential to produce a direct benefit to the pregnant or breastfeeding woman concerned, or to her embryo, foetus or child after birth, outweighing the risks and burdens involved;”
“(b) where research is undertaken on breastfeeding women, particular care is taken to avoid any adverse impact on the health of the child;”
“(c) no incentives or financial inducements are given to the subjects, except for compensation for expenses and loss of earnings directly related to the participation in the clinical investigation.”
5. Additional Measures: Article 67
“(1) Additional measures may be taken or maintained with regard to persons performing mandatory military service, persons deprived of their liberty, persons who, by judicial decision, cannot take part in clinical investigations, or persons in care homes.”
The Article says that additional measures may be taken; it does not list the content of the measures.
6. Clinical Investigations in Emergency Situations: Article 68
Article 68 makes an exception to Article 62(4)(e), Article 64(1)(a) and (b), and Article 65(1)(a) and (b). Where the decision to include the subject is taken at the time of the first intervention in accordance with the clinical investigation plan, this is done provided that all of the following conditions are met, and the information may be given after that decision:
“(a) due to the urgency of the situation, caused by a sudden life-threatening medical condition or other serious condition, the subject is unable to provide prior informed consent, and to receive prior information on the clinical investigation;”
“(b) there are scientific grounds to expect that participation of the subject in the clinical investigation will have the potential to produce a direct clinically relevant benefit for the subject resulting in a measurable health-related improvement alleviating the suffering and/or improving the health of the subject, or in the diagnosis of its condition;”
“(c) it is not possible within the therapeutic window to supply all prior information to, and obtain prior informed consent from, his or her legally designated representative;”
“(ç) the investigator certifies that he or she is not aware of any objections to participate in the clinical investigation previously expressed by the subject;”
“(d) the clinical investigation relates directly to the subject’s medical condition because of which it is not possible within the therapeutic window to obtain prior informed consent from the subject or from his or her legally designated representative and to supply prior information, and the clinical investigation is of such a nature that it may be conducted solely in emergency situations;”
“(e) the clinical investigation poses a minimal risk to, and imposes a minimal burden on, the subject in comparison with the standard treatment of the subject’s condition.”
Informed consent and information after the intervention:
“(2) Following an intervention pursuant to the first paragraph, informed consent in accordance with Article 63 shall be sought for the continued participation of the subject in the clinical investigation, and the information on the clinical investigation shall be given in accordance with the following requirements:”
“(a) with regard to incapacitated subjects and minors, informed consent shall be sought by the investigator from his or her legally designated representative without undue delay, and the information referred to in the second paragraph of Article 63 shall be given to the subject and to his or her legally designated representative as soon as possible.”
“(3) If the subject or, where applicable, his or her legally designated representative does not give consent, he or she shall be informed of the right to object to the use of data obtained from the clinical investigation.”
For other subjects, under subparagraph (b), consent is sought without undue delay from the subject or from his or her legally designated representative, whichever can be obtained earlier; if consent has been obtained from the legally designated representative, it is also sought from the subject as soon as he or she is capable of giving consent.
7. Compensation for Damage: Article 69
“(1) It shall be ensured that compensation systems for any damage suffered by a subject resulting from participation in a clinical investigation conducted in Türkiye are in place in the form of insurance, a guarantee, or a similar arrangement that is equivalent in terms of its purpose and appropriate to the nature and the extent of the risk.”
“(2) The sponsor and the investigator shall use the system referred to in the first paragraph in an appropriate manner.”
Scope: damage to subjects arising from participation in a clinical investigation conducted in Türkiye.
Form: insurance, a guarantee, or a similar arrangement equivalent in terms of its purpose and appropriate to the nature and extent of the risk.
Who uses it: the sponsor and the investigator.
Subparagraphs 64(1)(ç), 65(1)(ç) and 66(1)(c), in turn, exclude compensation for expenses and loss of earnings directly related to participation from the ban on incentives and financial inducements. For post-investigation clinical data, see our post on clinical evaluation and PMCF; for the protection of personal data, our post on confidentiality, trade secrets and personal data.
8. Frequently Asked Questions
Which Articles regulate the special groups in clinical investigations?
They are regulated in Articles 64 (incapacitated subjects), 65 (minors), 66 (pregnant or breastfeeding women), 67 (additional measures) and 68 (emergency situations) of the Tıbbi Cihaz Yönetmeliği.
From whom is consent obtained for an incapacitated subject or a minor?
Under 64(1)(a) and 65(1)(a), informed consent is obtained from their legally designated representatives. The incapacitated subject and the minor are also informed and take part in the consent procedure.
Can subjects be paid?
Under 64(1)(ç), 65(1)(ç) and 66(1)(c), no incentive or financial inducement is given, except for compensation for expenses and loss of earnings directly related to participation.
Can consent be obtained afterwards in an emergency?
If all the conditions in Article 68 are met, consent and information may follow the decision to include the subject. For continued participation, consent is sought under Article 63.
What system is required for damage to subjects?
Under Article 69, a compensation system is in place in the form of insurance, a guarantee, or a similar arrangement equivalent in terms of its purpose and appropriate to the nature and extent of the risk; the sponsor and the investigator use this system in an appropriate manner.
For the ÜTS registration of your devices: Medical Device ÜTS Registration Consultancy
Sources



